posit stock reaction expect clear posit stock reaction pg
deliv second straight strong quarter organ sale growth
unround like ex bp japan inventori build well
rise market expect signific gm upsid averag
organ sale growth pg best result sinc
downturn strong acceler vs averag sale growth
includ pg post
topline/gross profit/oper profit upsid vs consensu bp
adjust gm upsid vs consensu pg also rais ep guidanc bp
victori cpg environ estim gener come
fx highlight pg posit trade head quarter topline/gm
upsid result even higher qualiti expect pg
remain top pick hpc group
larg ep pg fiscal core ep
consensu mse high qualiti larg top-line upsid robust
organ sale growth bp gm beat drive oper
profit beat vs consensu organ sale growth un-round
includ bp japan time benefit ahead consensu
street expect two-year averag growth also acceler
vs top-line growth balanc price volum
mix price sequenti vs
report top-line beat boost better expect
gross margin expand larg bp yoy bp vs consensu
includ bp fx bp product bp price
bp commod bp fix cost leverag benefit
bp unfavor product mix sg sale decreas
bp yoy includ bp posit fx bp sale leverag
bp overhead market expens partial off-set bp
market invest bp inflat impact includ
increas digit invest incent compens cost net oper
profit beat consensu om bp y-o-i
strong segment result pg segment organ sale result better
expect across board upsid vs consensu segment beauti
strong volum price mix vs consensu
mse skin person organ sale mid-teen driven
growth super-premium sk-ii brand olay skin increas price
hair organ sale increas msd health volum
household person unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
price mix vs consensu mse
health dd due innov higher retail inventori build versu
base period cough cold season favor mix due higher
growth north america higher averag sell price oral
hsd premium innov increas posit mix fabric
volum price flat mix vs consensu mse
hsd growth fabric babi feminin
 famili organ sale volum price mix vs
consensu mse babi increas lsd due
devaluation-rel price increas posit mix growth premium
product partial off-set competit activ categori contract
certain market feminin famili organ sale increas hsd
due posit product mix innov higher price groom
volum price mix flat vs consensu mse
strong across board m-hsd result sizeabl area
weak north america groom groom segment
ep organ sale growth guidanc rais pg rais
organ sale growth guidanc vs prior all-in sale growth
also vs prior reflect modest neg impact fx
unchang like slightli wors un-round larg off-set posit
impact acquisit divestitur unchang pg rais core
ep growth guidanc y-o-i base impli
midpoint current
consensu mse view ep rais clearli posit
pg assum greater reinvest behind busi rais guidanc
peer ep estim move fx etc posit
pg posit ep revis balanc fiscal year pg rais
adjust free cash flow product vs prior pg still
expect pay billion dividend unchang repurchas
billion common share unchang
metric quarter
million except ep
sale
sale
sale
pt forecast organ sale growth go forward hpc
peer led improv us result build market share momentum better price
realiz continu cost save support bp om expansion/yr drive
hsd ep growth appli multipl ep slight premium pg
share vacil currenc commod volatil
